SCHEDULE 13G: BlackRock Discloses 5.5% Stake in Amylyx Pharmaceuticals
Beneficial Ownership Disclosure
BlackRock, Inc. has disclosed a beneficial ownership of 5.5% of Amylyx Pharmaceuticals, Inc.'s common stock, totaling 4,917,501 shares, as of June 30, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 4,917,501 shares of Amylyx Pharmaceuticals, Inc. common stock.
- This represents 5.5% of the total outstanding common stock of Amylyx Pharmaceuticals, Inc.
- BlackRock holds sole voting power over 4,827,647 shares and sole dispositive power over 4,917,501 shares.
- The shares are held in the ordinary course of business and were not acquired or held for the purpose of changing or influencing control of Amylyx Pharmaceuticals, Inc.
- BlackRock, Inc. is filing as a parent holding company, with various subsidiaries holding the securities, including BlackRock Advisors, LLC, BlackRock Fund Advisors, BlackRock Asset Management Ireland Limited, BlackRock Institutional Trust Company, National Association, BlackRock Financial Management, Inc., and BlackRock Investment Management, LLC.
- No single person's interest in the common stock held by BlackRock is more than five percent of the total outstanding common shares.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of beneficial ownership by a large institutional investor. It does not inherently convey positive or negative sentiment about the issuer's performance, but the presence of a significant institutional holder can be viewed as a stable factor.
Future Outlook
NA
Management Comments
- The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.
Industry Context
NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Update | BlackRock, Inc. updated its Power of Attorney, appointing new attorneys-in-fact for executing and filing ownership or control-person reporting documents, revoking a previous power of attorney dated April 30, 2023. | 2025-01-21 | Streamlines internal processes for SEC and other regulatory filings related to beneficial ownership, ensuring compliance and efficiency for BlackRock's reporting obligations. |
Stakeholder Impact
- Shareholders: The disclosure of a significant stake by a major institutional investor like BlackRock may be viewed positively, indicating institutional confidence or inclusion in passive investment vehicles.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous Power of Attorney revoked by BlackRock, Inc. |
| 2025-01-21 | Effective date of new Power of Attorney for BlackRock, Inc. |
| 2025-06-30 | Date of event which requires filing of this statement (beneficial ownership threshold met/crossed). |
| 2025-07-17 | Date of filing of this Schedule 13G by BlackRock, Inc. |
Keywords
Amylyx Pharmaceuticals, BlackRock, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Institutional Investor, Pharmaceuticals, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.